semaglutide vs empagliflozin Comparison of or Dulaglutide Versus for Risk for Death and Cardiovascular Outcomes Among Patients With Type 2 Diabetes: Two Target Trial Emulation Studies: Annals of Internal Medicine: Vol 178, No 7 In this large-scale real-world study,

The median followup was approximately 3940 months, and the primary endpoint was time to first MACE (CV death, nonfatal MI, or nonfatal stroke)

In clinical studies, people on bimagrumab experienced increases in lean mass and reductions in fat mass, even without dieting or exercise changes

adjusted for sex, age, race, medication type, comorbidities such as T2DM, CKD, HF, and obesity

When will I notice the results

They are just learning that these drugs work in the brain, not just the gut as originally expected, in unknown ways and for unknown duration, and adding unstudied intermittent usage creates a number of unknowns

What Is GLP-1 Weight Loss